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Abstract
Leukocyte ingress into the synovium is a key process in the pathogenesis of rheumatoid
arthritis and other inflammatory conditions. In this review, the role of endothelial cells in
leukocyte extravasation will be discussed, including the role of the most relevant cellular
adhesion molecules. These molecules play an important role in mediating leukocyte–
endothelial interactions. It is likely that different adhesive pathways are involved in different
steps of leukocyte adhesion to and migration through endothelia. Targeting of pathological
endothelial function, including leukocyte–endothelial adhesion, may be useful for the future
management of inflammatory arthritis.
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CAMs = cellular adhesion molecules; CLA = cutaneous leukocyte antigen; ESL = E-selectin ligand; HEV = high endothelial venule; ICAM =
intercellular adhesion molecule; IL = interleukin; LFA = lymphocyte function-associated antigen; PECAM = platelet–endothelial adhesion mole-
cule; PSGL = P-selectin ligand; RA = rheumatoid arthritis; TGF = transforming growth factor; TNF = tumor necrosis factor; VAP = vascular
adhesion protein; VCAM = vascular cell adhesion molecule.
http://arthritis-research.com/content/2/5/368
Introduction
Leukocyte extravasation through the endothelial barrier is
important in the pathogenesis of inflammatory disorders
such as rheumatoid arthritis (RA). Endothelial cells line the
lumina of vessels, thus separating and also connecting the
blood and the synovial tissue. It has become clear that, in
inflammation, endothelial cells are not only passive
bystanders but are active responders to various stimuli
(state of activation of leukocytes, exogenous cytokines,
endogenous endothelial mediators, and crosstalk between
adhesion molecules). Thus endothelia are targets for
inflammatory leukocytes and their mediators. In return,
endothelial cells themselves produce a number of inflam-
matory mediators, express cellular adhesion molecules
(CAMs) and therefore directly influence the action of leuko-
cytes and the outcome of the inflammatory response [1,2].
Endothelial cells are involved in a number of mechanisms
underlying arthritis. Various inflammatory mediators, pri-
marily pro-inflammatory cytokines including tumor necrosis
factor (TNF)-a and IL-1b, activate endothelial cells. In
response, there is an upregulation of endothelial CAMs in
RA, leading to increased leukocyte–endothelial interac-
tions [2–4].
In this review we discuss the role of endothelial cells, as
well as that of leukocyte–endothelial adhesion and migra-
tion in synovial inflammation. First we describe the general
characteristics of leukocyte–endothelial adhesion. Then
the role of the most relevant CAMs, as well as that of the
most important adhesive pathways determined by these
CAMs in arthritis is introduced. Finally we discuss poten-
tial strategies of targeting these mechanisms.http://arthritis-research.com/content/2/5/368
Leukocyte–endothelial interactions in
synovitis
The ingress of leukocytes into the synovium is an active
process mediated by a number of CAMs. The cascade of
events begins with the adhesion of neutrophils, lympho-
cytes and monocytes to the specialized, fenestrated syn-
ovial endothelium [4,5]. High endothelial venule (HEV)-like
microvessels, similar to HEVs in the primary lymphoid
organs, are present in the rheumatoid synovial tissue
[2,4,5]. Thus the process of leukocyte extravasation into
the synovium closely resembles physiological lymphocyte
‘homing’. After adhesion, leukocytes transmigrate through
the vessel wall into the synovium [6••,7••,8,9].
CAMs have been classified into a number of superfamilies.
However, most CAMs involved in endothelial adhesion
belong to three supergene familes, the integrin, selectin
and immunoglobulin families [6••,7••,8,9]. Leukocyte adhe-
sion to endothelial cells occurs in four distinct steps
[9,10] (Table 1):
1. Primary, relatively weak adhesion termed ‘rolling’
occurs within the first 1–2h. It is mediated by E-, P-
and L-selectins and their counter-receptors.
2. Leukocyte activation and triggering occurs next and is
due to the interactions between chemokine receptors
on leukocytes and proteoglycans on endothelial cells.
Platelet–endothelial adhesion molecule (PECAM)-1 (or
CD31) and the soluble platelet-activating factor (PAF)
are also involved in this step.
3. Activation-dependent, firm adhesion occurs within
4–6h. This interaction is mediated mostly by a4b1
integrin–vascular cell adhesion molecule (VCAM)-1 and
aLb2 integrin [or lymphocyte function-associated antigen
(LFA)-1]–intercellular adhesion molecule (ICAM)-1
interactions.
4. Transendothelial migration or diapedesis occurs when
secreted chemokines bind to endothelial heparan
sulphate glycosaminoglycans. Chemokines attract
endothelium-bound neutrophils and/or mononuclear
leukocytes preferentially. Integrins recognizing fibro-
nectin and laminin enable leukocyte extravasation
[9,10••]. Leukocyte adhesion to and migration through
the vascular endothelium result in the formation of
inflammatory infiltrates within the synovium [2,4,5].
Cellular adhesion molecules and pathways in
the rheumatoid synovium
Selectins contain an extracellular N-terminal domain related
to lectins, an epidermal growth factor-like domain and
moieties related to complement regulatory proteins [6••,7••,
8,9]. This superfamily of CAMs includes E-, P- and
L-selectin. Among these CAMs, E- and P-selectin are
present and cytokine-inducible on endothelial cells; they
are therefore markers of endothelial activation in inflamma-
tion [4,6••,7••,11]. E- and P-selectin ligands, such as
E-selectin ligand (ESL)-1, P-selectin ligand (PSGL)-1 and
cutaneous leukocyte antigen (CLA), contain sialylated
glycan motifs [12–14]. E-selectin mediates the adhesion of
neutrophils and, to a smaller extent, eosinophils, monocytes
and some memory T cells to endothelia [15]. E-selectin has
been associated with dermal and pulmonary inflammation
in animal models [16,17]. We and others found an abun-
dant expression of E-selectin in the synovial tissues
[18•,19]. P-selectin is constitutively present on the mem-
brane of endothelial Weibel–Palade bodies and is involved
in neutrophil and monocyte adhesion to endothelium
[6••,7••,20,21•]. Because the upregulation of P-selectin
expression on endothelia occurs within seconds, this CAM
is thought to be involved in the very early phases of adhe-
sion [22]. We demonstrated P-selectin expression on RA
synovial endothelial cells [23].
Integrins are ab heterodimers and are classified into fami-
lies with respect to their common b subunits (b1–b8)
[6••,7••,8,9]. Among these CAMs, b1 and b3 integrins are
expressed on endothelial cells. These integrins (a1–9b1,
aVb3) mediate cell adhesion to ECM components, includ-
ing various types of collagen, laminin, fibronectin, fibrino-
gen, tenascin, vitronectin and thrombospondin [6••,7••,8].
Not only are integrins involved in endothelial cell adhesion
to ECM, but sometimes they are able to mediate cell–cell
contacts. In the latter situation, integrins bind to CAMs
belonging to the immunoglobulin superfamily. The two
most relevant receptor–counter-receptor pairs are a4b1
integrin recognizing VCAM-1 and b2 integrins (LFA-1 and
Mac-1) binding to ICAM-1 and ICAM-3 [6••,7••,24]. We
and others have demonstrated the abundant expression of
endothelial integrins in synovial inflammation [4,5,23–26].
Table 1
Distinct steps during leukocyte emigration into the arthritic
synovium
Step Factors on endothelium Factors on leukocytes
Rolling P-selectin PSGL-1
E-selectin ESL-1
L-selectin ligand ? Sialyl Lewis-X,
CLA,
L-selectin
Activation Chemokines (IL-8, Cytokine and
MCP-1), PAF chemokine receptors
PECAM-1 PECAM-1
E-selectin PSGL-1, ESL-1
Firm adhesion ICAM-1, VCAM-1 b1, b2 and b7 integrins
Diapedesis ICAM-1 b1, b2 and b7 integrins
VCAM-1 PECAM-1
PECAM-1
MCP-1 = monocyte chemotactic protein-1.Arthritis Research    Vol 2 No 5 Szekanecz and Koch
VCAM-1, a ligand for the integrins a4b1 and a4b7, is consti-
tutively expressed on resting endothelial cells but its
expression is markedly upregulated by IL-1, TNF-a and IL-4
[4,27]. Abundant VCAM-1 expression has been associated
with inflammatory infiltrates [28]. We and others have
reported the expression of VCAM-1 on synovial endothelial
cells, and also on macrophages in RA [4,18•,29].
ICAM-1 serves as a ligand for the b2 integrins LFA-1
(aLb2), Mac-1 (aMb2) and p150,95 (aXb2) [6••,7••,8,9].
ICAM-1 shows basal expression on endothelial cells;
however, its expression can be further stimulated by IL-1,
TNF-a and interferon-g [30•]. In vitro, the maximal expres-
sion of ICAM-1 on endothelia is observed later (more than
24h) than that of E-selectin or VCAM-1 [1]. ICAM-1 is
highly expressed on endothelial cells in inflammatory sites
such as the inflamed synovium in situ [4,16,18•].
Other CAMs mediating endothelial cell adhesion to cells
in the inflamed synovium include LFA-3, PECAM-1
(CD31), CD44, CD66, vascular adhesion protein (VAP)-1,
endoglin, ICAM-3 and possibly others [4,5,6••,7••,8,
31–34]. LFA-3 and its counter-receptor CD2 are
members of the immunoglobulin superfamily. Whereas
CD2 is a T cell marker, LFA-3 is present on endothelial
cells. The CD2/LFA-3 adhesion pathway is involved in
various inflammatory responses including synovitis [4,31].
PECAM-1, another member of the immunoglobulin super-
gene family, mediates homotypic adhesion by binding to
PECAM-1, and heterotypic adhesion by recognizing the
aVb3 integrin [6••,7••,8,35]. PECAM-1 is a marker of acti-
vated endothelium; we found it in large quantities in the
RA synovium [23,33]. CD44 is a receptor for hyaluronate
[6••,7••,8] and is present on activated endothelial cells in
inflammation including RA [23,36]. VAP-1 was originally
isolated from synovial endothelial cells. The expression of
VAP-1 is increased in RA [32]. Endoglin is a receptor for
transforming growth factor (TGF)-b1 and TGF-b3, and is
involved in endothelial adhesion. We have detected
endoglin on most endothelial cells in the RA synovium
[34]. ICAM-3 is a leukocyte CAM that is a known ligand
for LFA-1. It is absent from resting endothelial cells.
However, we could detect ICAM-3 on a portion of RA syn-
ovial endothelial cells [24,37], which suggests the possi-
ble role of endothelial ICAM-3 in synovitis. Thus a number
of CAMs might have a role in leukocyte–endothelial inter-
actions underlying inflammatory synovitis.
In RA, the most important adhesive interactions between
leukocytes and endothelial cells are determined by
a4b1–VCAM-1,  b2 integrin (LFA-1, Mac-1)–ICAM-1 and
CD2–LFA-3 interactions, as well as E- and P-selectins,
CD44, PECAM-1 and their ligands. These adhesion path-
ways are summarized in Table 2.
Leukocyte–endothelial adhesion: a possible
target for antirheumatic therapy
There have been several attempts to therapeutically block
leukocyte adhesion to endothelium, and thus to control
inflammation. Adhesion and the expression of CAMs can
Table 2
The most important leukocyte–endothelial adhesion pathways in rheumatoid arthritis
Adhesion molecule 
superfamily Receptor on endothelium Ligand(s)
Integrin b1 integrins (most)  Extracellular matrix components (laminin, fibronectin, collagen, vitronectin, etc.)
a4b1 integrin VCAM-1, fibronectin
b2 integrins (LFA-1, Mac-1) ICAM-1, ICAM-3
aVb3 integrin Extracellular matrix components (fibronectin, fibrinogen, thrombospondin)
Immunoglobulin ICAM-1, ICAM-3 b2 integrins: LFA-1, Mac-1
VCAM-1 a4b1 and a4b7
LFA-3 CD2
PECAM-1 (CD31) Homophilic, avb3
CD66a–e ?
Selectin E-selectin ESL-1, PSGL-1, CLA
P-selectin PSGL-1
Other CD44 Hyaluronic acid
Endoglin TGF-b
VAP-1 ?http://arthritis-research.com/content/2/5/368
be targeted with currently used antirheumatic agents, spe-
cific monoclonal antibodies, purified protein or carbohy-
drate ligands, soluble adhesion molecules, gene therapy
or other methods [4]. Leukocyte–endothelial adhesion and
adhesion molecules have been targeted in vitro, in animal
models of arthritis, and recently in humans.
With regard to studies in vitro, dexamethasone (a gluco-
corticoid compound) and bucillamine (a D-penicillamine
derivative) inhibit T cell adhesion to cultured synovial
fibroblasts [38•,39]. Corticosteroids can also suppress
TNF-a-induced ICAM-1 expression on these fibroblasts
[40]. Gold sodium thiomalate inhibits cytokine-induced
VCAM-1 and E-selectin expression on endothelia [41].
Clarithromycin markedly suppresses the upregulated
expression of ICAM-1, VCAM-1 and LFA-3 on human syn-
ovial fibroblasts [42]. Purified CAM ligands such as inte-
grin-binding peptides block cartilage chondrolysis [43•].
Antisense oligonucleotides block ICAM-1, VCAM-1 and
E-selectin expression on endothelial cells [44••].
In animal models, methotrexate blocks leukocyte–endothe-
lial adhesion and leukocyte extravasation [45]. Antibodies
against ICAM-1 and the b2 integrin subunit (CD18) inhib-
ited leukocyte ingress into the synovium in rats, and also
the development of arthritis in rats and rabbits [46,47•,48].
Anti-ICAM-1 antibody also inhibited murine collagen-
induced arthritis [49]. Anti-a4b1 integrin antibodies sup-
pressed leukocyte migration to joints and diminished
adjuvant-induced arthritis in rats [48,50•,51]. Anti-CD44
antibodies markedly decreased the severity of murine pro-
teoglycan-induced arthritis [52,53•].
In humans, oral methoxypsoralen combined with intra-
articular UV-A irradiation downregulated ICAM-1, VCAM-1
and E-selectin expression in the RA synovium [54]. Gold
salts inhibited synovial E-selectin expression in RA [55]. In
a recent series of studies, 32 patients with longstanding
RA that had been resistant to conventional therapy were
treated with anti-ICAM-1 monoclonal antibody; there was
a transient improvement in the status of these patients
[56••]. An even greater effect of this antibody was
observed when treating 10 patients who had early or indo-
lent RA [57]. Anti-cytokine targeting in RA might also influ-
ence the production of synovial adhesion molecules. For
example, treatment of RA patients with monoclonal anti-
body against TNF-a resulted in decreased serum levels of
soluble ICAM-1 and E-selectin in these patients [58•].
Summary
Leukocyte–endothelial adhesion has a central role in
leukocyte extravasation, a key feature of inflammation
including arthritis. A number of adhesion molecules,
among which are integrins, selectins and immunoglobu-
lins, act in concert and regulate the sequence of distinct
steps. According to the four-step model of leukocyte–
endothelial interactions, the selectin-dependent leukocyte
rolling is followed by integrin-dependent leukocyte activa-
tion, firm adhesion and then transmigration. The most
important adhesive pathways are determined by recep-
tor–ligand pairs including endothelial E- and P-selectin
and their respective sialylated ligands; a4b1 integrin and
VCAM-1; and LFA-1 or Mac-1 integrin and ICAM-1. The
presence of various CAM pairs and the existence of dis-
tinct steps of rolling, activation, adhesion and migration
account for the diversity and specificity of
leukocyte–endothelial interactions. There have been
several attempts to interfere therapeutically with the cellu-
lar and molecular mechanisms described above. Most
studies have been performed with animal models of
various types of inflammation. A limited number of human
clinical trials, such as that with anti-ICAM-1 antibody in
RA, have given promising results. Specific targeting of
pathological endothelial function might be useful for the
future management of inflammatory arthritis.
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